Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts

详细信息    查看全文

• 作者：Shinsuke Hanatani (1)
  Yasuhiro Izumiya (1)
  Seiji Takashio (1)
  Sunao Kojima (1)
  Megumi Yamamuro (1)
  Satoshi Araki (1)
  Taku Rokutanda (1)
  Kenichi Tsujita (1)
  Eiichiro Yamamoto (1)
  Tomoko Tanaka (1)
  Shinji Tayama (1)
  Koichi Kaikita (1)
  Seiji Hokimoto (1)
  Seigo Sugiyama (1)
  Hisao Ogawa (1)
  
• 关键词：Biomarker ; Cytokine ; Hypertension ; Heart failure
• 刊名：Heart and Vessels
• 出版年：2014
• 出版时间：March 2014
• 年：2014
• 卷：29
• 期：2
• 页码：231-237
• 全文大小：340 KB
• 参考文献：1. Misawa K, Nitta Y, Matsubara T, Oe K, Kiyama M, Shimizu M, Mabuchi H (2002) Difference in coronary blood flow dynamics between patients with hypertension and those with hypertrophic cardiomyopathy. Hypertens Res 25:711-16 CrossRef
  2. Maron BJ (2002) Hypertrophic cardiomyopathy: a systematic review. JAMA 287:1308-320
  3. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B, Pfeffer MA, Re RN, Roccella EJ, Savage D, Shub C (1992) The heart in hypertension. N Engl J Med 327:998-008 CrossRef
  4. Toshima H, Koga Y, Yoshioka H, Akiyoshi T, Kimura N (1975) Echocardiographic classification of hypertensive heart disease. A correlative study with clinical features. Jpn Heart J 16:377-93 CrossRef
  5. Bahler AS, Teichholz LE, Gorlin R, Herman MV (1977) Correlations of electrocardiography and echocardiography in determination of left ventricular wall thickness: study of apparently normal subjects. Am J Cardiol 39:189-95 CrossRef
  6. Dunn FG, Chandraratna P, deCarvalho JG, Basta LL, Frohlich ED (1977) Pathophysiologic assessment of hypertensive heart disease with echocardiography. Am J Cardiol 39:789-95 CrossRef
  7. Shapiro LM, McKenna WJ (1983) Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. J Am Coll Cardiol 2:437-44 CrossRef
  8. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 94:11514-1519 CrossRef
  9. Hsiao EC, Koniaris LG, Zimmers-Koniaris T, Sebald SM, Huynh TV, Lee SJ (2000) Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol 20:3742-751 CrossRef
  10. Schober A, B?ttner M, Strelau J, Kinscherf R, Bonaterra GA, Barth M, Schilling L, Fairlie WD, Breit SN, Unsicker K (2001) Expression of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in the perinatal, adult, and injured rat brain. J Comp Neurol 439:32-5 CrossRef
  11. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC (2006) The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 98:351-60 CrossRef
  12. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kanwischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudanna C, Hogg N, Vestweber D, Wollert KC (2011) GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 17:581-88 CrossRef
  13. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD (2006) GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98:342-50 CrossRef
  14. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L (2007) Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 115:962-71 CrossRef
  15. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, Ponikowski P, Filippatos GS, Rozentryt P, Drexler H, Anker SD, Wollert KC (2007) Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50:1054-060 CrossRef
  16. Stahrenberg R, Edelmann F, Mende M, Kocksk?mper A, Düngen HD, Lüers C, Binder L, Herrmann-Lingen C, Gelbrich G, Hasenfuss G, Pieske B, Wachter R (2010) The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail 12:1309-316 CrossRef
  17. Eitel I, Blase P, Adams V, Hildebrand L, Desch S, Schuler G, Thiele H (2011) Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: insights from cardiovascular magnetic resonance. Heart 97:632-40 CrossRef
  18. Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B, Olofsson S, Venge P, Larsson A, Hulthe J, Elmgren A, Wollert KC (2009) Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 30:2346-353 CrossRef
  19. Wang X, Yang X, Sun K, Chen J, Song X, Wang H, Liu Z, Wang C, Zhang C, Hui R (2010) The haplotype of the growth-differentiation factor 15 gene is associated with left ventricular hypertrophy in human essential hypertension. Clin Sci (Lond) 118:137-45 CrossRef
  20. Xue H, Fu Z, Chen Y, Xing Y, Liu J, Zhu H, Zhou X (2012) The association of growth differentiation factor-15 with left ventricular hypertrophy in hypertensive patients. PLoS ONE 7:e46534–e46539 CrossRef
  21. Montoro-García S, Hernández-Romero D, Jover E, García-Honrubia A, Vilchez JA, Casas T, Martínez P, Climent V, Caballero L, Valdés M, Marín F (2012) Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. Eur J Intern Med 23:169-74 CrossRef
  22. Hen Y, Iguchi N, Machida H, Takada K, Utanohara Y, Sumiyoshi T (2012) High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Heart Vessels. doi:10.1007/S00380-012-0300-3
  23. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C (1986) Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 55:575-81 CrossRef
  24. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440-463 CrossRef
  25. Sadanaga T, Mitamura H, Kohsaka S, Ogawa S (2012) Steady-state B-type natriuretic peptide levels in patients with atrial fibrillation of various clinical backgrounds. Heart Vessels 27:280-86 CrossRef
  26. Cuspidi C, Meani S, Fusi V, Valerio C, Catini E, Sala C, Sampieri L, Magrini F, Zanchetti A (2005) Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study. J Hypertens 23:875-82 CrossRef
  27. Yu CM, Sanderson JE, Marwick TH, Oh JK (2007) Tissue Doppler imaging a new prognosticator for cardiovascular diseases. J Am Coll Cardiol 49:1903-914 CrossRef
  28. Ogino K, Ogura K, Kinugawa T, Osaki S, Kato M, Furuse Y, Kinugasa Y, Tomikura Y, Igawa O, Hisatome I, Shigemasa C (2004) Neurohumoral profiles in patients with hypertrophic cardiomyopathy: differences to hypertensive left ventricular hypertrophy. Circ J 68:444-50 CrossRef
  29. Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, Cohn JN (2004) Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation 109:984-89 CrossRef
  
• 作者单位：Shinsuke Hanatani (1)
  Yasuhiro Izumiya (1)
  Seiji Takashio (1)
  Sunao Kojima (1)
  Megumi Yamamuro (1)
  Satoshi Araki (1)
  Taku Rokutanda (1)
  Kenichi Tsujita (1)
  Eiichiro Yamamoto (1)
  Tomoko Tanaka (1)
  Shinji Tayama (1)
  Koichi Kaikita (1)
  Seiji Hokimoto (1)
  Seigo Sugiyama (1)
  Hisao Ogawa (1)
  
  1. Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan
  
• ISSN：1615-2573

文摘

To distinguish hypertrophic cardiomyopathy (HCM) from hypertensive left ventricular hypertrophy (H-LVH) based on a morphological examination is often challenging. Growth differentiation factor 15 (GDF-15) is a novel diagnostic and prognostic biomarker for several cardiovascular diseases. In patients with LVH, GDF-15 promises to be a useful biomarker to distinguish between HCM and H-LVH. We evaluated 93 patients with H-LVH, 28 with HCM, and 28 disease control individuals. Serum GDF-15 concentrations were measured with an enzyme-linked immunosorbent assay. Circulating GDF-15 levels were significantly higher in patients with H-LVH than with HCM (P?=?0.003). On the other hand, values for plasma B-type natriuretic peptide (BNP) levels were significantly lower in patients with H-LVH than with HCM (P = 0.004). Serum GDF-15 and plasma BNP levels positively correlated in patients with H-LVH but not with HCM. Multivariate logistic regression analysis revealed GDF-15 (odds ratio 12.06, confidence interval 1.85-8.77, P < 0.01) as an independent predictor of H-LVH among patients with LVH. In receiver-operating characteristic analysis, GDF-15 achieved an area under the curve of 0.70 for the identification of H-LVH. We found that GDF-15 might be a useful biomarker for discriminating HCM from H-LVH. Understanding serum GDF-15 values may have clinical utility for patients with LVH because the therapeutic strategies for treating HCM and H-LVH differ.